Items tagged with Treatment

High prevalence of pre-XDR-TB in patients who didn't respond to treatment: Study (post)

Study of 600 TB patients in Mumbai found 51% with pre-XDR-TB and 15.5% with MDR-TB. Whole genome sequencing crucial for accurate treatment decisions.

Experts develop immune-enhancing therapies to target TB (post)

Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease. In a presentation at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona (27–30 April), Associate Professor Susanna Brighenti, Center for Infectious Medicine (CIM), ANA Futura at the Karolinska Institutet, Stockholm, Sweden, presents work being done in this area by a collaboration of scientists.

Johnson & Johnson receives positive CHMP opinion recommending full approval for SIRTURO® (bedaquiline) for treatment of multidrug-resistant TB (post)

-- CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation

-- Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies

Early program experience in the United States with four-month rifapentine and moxifloxacin–based TB treatment (post)

In 2020, a multicountry phase III randomized controlled clinical trial demonstrated the efficacy and safety of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin, and pyrazinamide (HPMZ) for the treatment of drug-sensitive TB.

SMART4TB survey: Share your perspective on TB treatment language (post)

SMART4TB wants to hear from you about the best person-centered language to describe TB treatment that takes severity and risk factors into account when coming up with a treatment plan. You are invited to complete a brief, five-minute questionnaire which can be accessed here.

Latest TB research publications (post)

New polymer-based drug delivery system developed for TB (post)

The formulation was developed through a single emulsion solvent evaporation technique and offers new delivery approach which could improve patient compliance, the paper stated.

Influenza-like reactions to latent TB treatment not mediated by drug antibodies (post)

In patients with latent tuberculosis, influenza-like reactions following treatment with isoniazid plus rifapentine or isoniazid alone were not associated with the presence of antibodies against isoniazid, rifapentine, and rifapentine metabolite.

Latest TB research publications (post)

FDA grants traditional approval to TB treatment Sirturo (post)

The Food and Drug Administration (FDA) has granted traditional approval to Sirturo^® (bedaquiline) for use as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid.